Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esuberaprost - Lung Biotechnology

Next Previous
X
Search
Drug Profile

Esuberaprost - Lung Biotechnology

Alternative Names: 314d; APS-314d; Beraprost Sodium 314d Modified Release; Beraprost-314d; BPS-314d-MR; Esuberaprost potassium; L-314d-QID

Latest Information Update: 28 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toray
  • Developer Lung Biotechnology
  • Class 3-ring heterocyclic compounds; Alkynes; Antihypertensives; Antiplatelets; Benzofurans; Butyric acids; Cardiovascular therapies; Cyclopentanes; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Pulmonary arterial hypertension

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension(In volunteers) in Unknown (PO, Tablet)
  • 07 Sep 2020 Lung Biotechnology terminates the phase III BEAT OLE trial in Pulmonary arterial hypertension in USA and Israel, due to failure in efficacy of esuberaprost sodium in NCT01908699 trial (NCT03657095)
  • 02 Jun 2019 Los Angeles Biomedical Research Institute and Lung Biotechnology completes a phase II compassionate use trial for Pulmonary arterial hypertension in USA (NCT01966302)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top